• Something wrong with this record ?

Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort

M. Zaliova, J. Stuchly, L. Winkowska, A. Musilova, K. Fiser, M. Slamova, J. Starkova, M. Vaskova, O. Hrusak, L. Sramkova, J. Stary, J. Zuna, J. Trka,

. 2019 ; 104 (7) : 1396-1406. [pub] 20190110

Language English Country Italy

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV15-30626A MZ0 CEP Register

Novel biological subtypes and clinically important genetic aberrations (druggable lesions, prognostic factors) have been described in B-other acute lymphoblastic leukemia (ALL) during the last decade; however, due to a lack of studies on unselected cohorts, their population frequency and mutual associations still have to be established. We studied 110 consecutively diagnosed and uniformly treated childhood B-other patients using single nucleotide polymorphism arrays and whole exome/transcriptome sequencing. The frequency of DUX4-rearranged, BCR-ABL1-like, ZNF384-rearranged, ETV6-RUNX1-like, iAMP21 and MEF2D-rearranged subtypes was 27%, 15%, 5%, 5%, 4%, and 2%, respectively; 43% of cases were not classified into any of these subtypes (B-rest). We found worse early response to treatment in DUX4-rearranged leukemia and a strong association of ZNF384-rearranged leukemia with B-myeloid immunophenotype. Of the druggable lesions, JAK/STAT-class and RAS/RAF/MAPK-class aberrations were found in 21% and 43% of patients, respectively; an ABL-class aberration was found in one patient. A recently described negative prognostic factor, IKZF1plus , was found in 14% of patients and was enriched in (but not exclusive for) BCR-ABL1-like subtype. PAX5 fusions (including 4 novel), intragenic amplifications and P80R mutations were mutually exclusive and only occurred in the B-rest subset, altogether accounting for 20% of the B-other group. PAX5 P80R was associated with a specific gene expression signature, potentially defining a novel leukemia subtype. Our study shows unbiased European population-based frequencies of novel ALL subtypes, recurrent (cyto)genetic aberrations and their mutual associations. This study also strengthens and widens the current knowledge of B-other ALL and provides an objective basis for optimization of current genetic diagnostics.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023848
003      
CZ-PrNML
005      
20201214131421.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.204974 $2 doi
035    __
$a (PubMed)30630978
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Zaliova, Marketa $u CLIP - Childhood Leukaemia Investigation Prague jan.trka@lfmotol.cuni.cz marketa.zaliova@lfmotol.cuni.cz. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University. University Hospital Motol, Prague, Czech Republic.
245    10
$a Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort / $c M. Zaliova, J. Stuchly, L. Winkowska, A. Musilova, K. Fiser, M. Slamova, J. Starkova, M. Vaskova, O. Hrusak, L. Sramkova, J. Stary, J. Zuna, J. Trka,
520    9_
$a Novel biological subtypes and clinically important genetic aberrations (druggable lesions, prognostic factors) have been described in B-other acute lymphoblastic leukemia (ALL) during the last decade; however, due to a lack of studies on unselected cohorts, their population frequency and mutual associations still have to be established. We studied 110 consecutively diagnosed and uniformly treated childhood B-other patients using single nucleotide polymorphism arrays and whole exome/transcriptome sequencing. The frequency of DUX4-rearranged, BCR-ABL1-like, ZNF384-rearranged, ETV6-RUNX1-like, iAMP21 and MEF2D-rearranged subtypes was 27%, 15%, 5%, 5%, 4%, and 2%, respectively; 43% of cases were not classified into any of these subtypes (B-rest). We found worse early response to treatment in DUX4-rearranged leukemia and a strong association of ZNF384-rearranged leukemia with B-myeloid immunophenotype. Of the druggable lesions, JAK/STAT-class and RAS/RAF/MAPK-class aberrations were found in 21% and 43% of patients, respectively; an ABL-class aberration was found in one patient. A recently described negative prognostic factor, IKZF1plus , was found in 14% of patients and was enriched in (but not exclusive for) BCR-ABL1-like subtype. PAX5 fusions (including 4 novel), intragenic amplifications and P80R mutations were mutually exclusive and only occurred in the B-rest subset, altogether accounting for 20% of the B-other group. PAX5 P80R was associated with a specific gene expression signature, potentially defining a novel leukemia subtype. Our study shows unbiased European population-based frequencies of novel ALL subtypes, recurrent (cyto)genetic aberrations and their mutual associations. This study also strengthens and widens the current knowledge of B-other ALL and provides an objective basis for optimization of current genetic diagnostics.
650    _2
$a mladiství $7 D000293
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    12
$a chromozomální aberace $7 D002869
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genomika $x metody $7 D023281
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a pre-B-buněčná leukemie $x epidemiologie $x genetika $x patologie $7 D015452
650    _2
$a prognóza $7 D011379
650    12
$a transkriptom $7 D059467
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stuchly, Jan $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Winkowska, Lucie $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Musilova, Alena $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Fiser, Karel $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Slamova, Martina $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Starkova, Julia $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Vaskova, Martina $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University.
700    1_
$a Hrusak, Ondrej $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Sramkova, Lucie $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Stary, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Zuna, Jan $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Trka, Jan $u CLIP - Childhood Leukaemia Investigation Prague jan.trka@lfmotol.cuni.cz marketa.zaliova@lfmotol.cuni.cz. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University. University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 7 (2019), s. 1396-1406
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30630978 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131419 $b ABA008
999    __
$a ok $b bmc $g 1596167 $s 1114524
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 7 $d 1396-1406 $e 20190110 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a NV15-30626A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...